Subject(s)
Antigen-Antibody Reactions , Leukemia, Lymphoid/immunology , Adolescent , Antibody Formation/drug effects , Antigen-Antibody Reactions/drug effects , BCG Vaccine/therapeutic use , Child , Child, Preschool , Cytotoxicity, Immunologic/drug effects , Humans , Immunity, Cellular/drug effects , Leukemia, Lymphoid/drug therapySubject(s)
Immunotherapy/methods , Leukemia, Lymphoid/immunology , Cell Adhesion/drug effects , Child , Drug Therapy, Combination , Humans , Immunity, Cellular/drug effects , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Leukemia, Lymphoid/therapy , Leukocytes/drug effects , Leukocytes/immunologySubject(s)
Immunotherapy/methods , Leukemia, Lymphoid/immunology , Adolescent , Antibodies, Neoplasm/administration & dosage , Antibody Formation , Child , Evaluation Studies as Topic , Female , History, Medieval , Humans , Immunity, Cellular , Leukemia, Lymphoid/therapy , Leukocyte Count , Male , Prednisolone/administration & dosage , Time FactorsABSTRACT
Comparative effectiveness of maintenance chemo- and chemo-immunotherapy with Soviet strain of BCG vaccine was studied on 75 children with acute lymphoid leukemia (ALL). The patients were divided in two groups: I -- 25 patients received maintenance chemotherapy plus BCG; II -- 50 patients were given sole form of maintenance chemotherapy. Median duration of remission in the group I -- 36.3 +/- 4.2 months; in the group II -- 13.8 +/- 1.9 (p less than 0.001); median duration of life -- 45.1 +/- 3.7 and 23.9 +/- 3.3 (p less than 0.001) respectively. In 6 out of 25 patients (group I) the first complete remission continues for more than 6 years (median duration of remission -- 82.5 and life -- 85.3 months). In the group II the first remission continues only in 1 patient out of 50.
Subject(s)
Antineoplastic Agents/therapeutic use , BCG Vaccine/therapeutic use , Leukemia, Lymphoid/therapy , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Immunotherapy , MaleABSTRACT
Studies on the cell immunity in patients with acute leukemia were conducted in two functionally different tests: in cytotoxic reaction of lymphocytes and in the reaction of inhibition of leucocytes adherence which manifest accordingly the killer and antigen-reactive function of immunocompetent cells. There was found a statistically reliable enhancement of lymphocytes reactivity in patients with acute leukemia against leukemia-associated antigens compared with lymphocytes of healthy donors. The cytotoxic activity of lymphocytes was enhanced during the complete remission and before the recurrence, whereas the potential of antigen-reactive cells was reduced during the complete remission and against the background of the recurrence.
Subject(s)
Immunity, Cellular , Leukemia/immunology , Acute Disease , Adolescent , Cell Adhesion , Child , Child, Preschool , Cytotoxicity, Immunologic , Humans , Killer Cells, Natural/immunology , Leukocytes/immunology , Lymphocytes/immunologyABSTRACT
On the basis of experimental results an immunological method of acute lymphoblastic leukemia treatment by means of specific immunity regulation was designed. The administration of antibodies (immunoglobulins) with prednisolone to patients induced 100% remissions in a comparatively short time. None of the patients treated with immunoprednisolone therapy had neuroleukemia. The immunological findings indicate that the therapeutic effect depends on the "deblocking" action of the applied immune preparation.
Subject(s)
Antibodies, Neoplasm/administration & dosage , Leukemia, Lymphoid/therapy , Acute Disease , Adolescent , Brain Neoplasms/prevention & control , Child , Child, Preschool , Female , Humans , Immunoglobulin G/administration & dosage , Immunoglobulin M/administration & dosage , Immunotherapy , Leukemia, Lymphoid/drug therapy , Male , Prednisone/administration & dosageSubject(s)
Immunotherapy , Leukemia, Lymphoid/therapy , Leukemia, Myeloid, Acute/therapy , Adolescent , Child , Child, Preschool , Female , Humans , Immunotherapy/methods , MaleABSTRACT
Comparative results of chemo- and chemoimmunotherapy with Soviet strain of BCG vaccine in children with acute leukemia are presented. The immunotherapeutical regimen includes 20 intracutaneous injections of 0.1 mg BCG vaccine given weekly during 5--6 months with subsequent 5--6 months intervals simultaneously with maintenance chemotherapy. In the control group children were only given conventional chemotherapy. The median duration of remission and survival in patients who had received BCG chemoimmunotherapy was 25.2 +/- 1.5 and 32.3 +/- 1.2 months respectively. In the group of patients with chemotherapy alone--13.2 +/- 0.9 and 21.8 +/- 1.1 months respectively (p less than 0.01). The best results were obtained in children who had received before BCG immunotherapy neuroleukemia prophylactic treatment.
Subject(s)
Antineoplastic Agents/therapeutic use , BCG Vaccine/therapeutic use , Leukemia, Lymphoid/therapy , Adolescent , Brain Neoplasms/prevention & control , Child , Child, Preschool , Drug Therapy, Combination , Female , Humans , Male , Mercaptopurine/therapeutic use , Methotrexate/therapeutic use , Prednisolone/therapeutic use , Remission, Spontaneous , Time Factors , Vincristine/therapeutic useABSTRACT
A possibility of detecting embryonic leukemic antigen on human leukemic blast cells in an acute human leukemia cytotoxicity test with the sera and 7S and 19S serum immunoglobulins of the placental blood was studied. The presence on the blast cells of patients suffering from acute leukemia of an antigen detectable by antibodies of placental blood (of parturients) was demonstrated; this antigen was absent on the leukocytes of healthy donors.